Skip to main content
. 2022 Mar 8;12:799501. doi: 10.3389/fcimb.2022.799501

Table 3.

Vaginal fluid TFV concentrations (ng/mg) and vaginal tissue TFV (ng/mg) and TFV-DP (fmol/mg) concentrations among TFV/LNG IVR users (cyclic and continuous cohorts combined) with either Lactobacillus dominated (LbD) or CST IVA/B microbiota.

Visit LbD microbiota CST IVA/B microbiota p value
N Mean SD Median N Mean SD Median
TFV in vaginal fluid (ng/mg)
Month 1 15 1,577 823 1,502 16 3,981 3,337 3,135 0.02
Month 2 14 1,524 1,287 1,364 16 5,926 6,345 3,800 <0.01
Month 3 12 1,647 607 1,423 18 1,463 2,696 351 0.02
TFV in vaginal tissue (ng/mg)
24 h post IVR insertion 5 40.99 52.39 25.6 7 21.22 18.11 13.72 0.87
48 h post IVR insertion 7 52.9 55.31 25.81 4 19.53 16.41 18.13 0.64
72 h post IVR insertion 6 184.51 191.99 130.3 7 42.88 48.83 23.32 0.87
Month 3 11 189 217 103 19 60 144 5 < 0.01
TFV-DP in vaginal tissue (fmol/mg)
24 h post IVR insertion 5 408.42 393.73 436.83 7 265.78 277.7 192.57 0.63
48 h post IVR insertion 7 1,936.04 2,621.49 775.32 4 167.05 102.41 151.76 <0.05
72 h post IVR insertion 6 5,566.12 6,319.33 2,833.98 7 4,124.73 6,846.32 2,039.38 0.63
Month 3 11 15,491.9 21,133.3 5,877.7 19 1,457.67 2,599.59 212.38 <0.01